Prosecution Insights
Last updated: May 29, 2026

Examiner: SHIAO, YIH-HORNG

Tech Center 1600 • Art Units: 1621 1623 1672 1673 1691 1693

This examiner grants 73% of resolved cases

Performance Statistics

72.6%
Allow Rate
+12.6% vs TC avg
983
Total Applications
+75.6%
Interview Lift
870
Avg Prosecution Days
Based on 953 resolved cases, 2023–2026

Rejection Statute Breakdown

0.7%
§101 Eligibility
9.0%
§102 Novelty
56.8%
§103 Obviousness
2.7%
§112 Clarity

Currently Pending Office Actions

App #TitleStatusAssignee
19347574 COMPLEXING AGENT SALT FORMULATIONS OF PHARMACEUTICAL COMPOUNDS Non-Final OA Bexson Biomedical, Inc.
18008684 IMPROVED DEMINERALIZATION OF FERMENTATION BROTHS AND PURIFICATION OF FINE CHEMICALS SUCH AS OLIGOSACCHARIDES Final Rejection BASF SE
18225010 METHODS FOR PRODUCING SYNTHETIC OLIGONUCLEOTIDES AND REMOVAL AGENTS FOR REMOVING IMPURITIES FROM ORGANIC WASH SOLVENTS USED IN OLIGONUCLEOTIDE SYNTHESIS Non-Final OA Honeywell International Inc.
18254488 POLYROTAXANE HAVING HYDROXY GROUP OR SULFO GROUP Non-Final OA NATIONAL UNIVERSITY CORPORATION TOKYO MEDICAL AND DENTAL UNIVERSITY
17603908 METHOD AND KIT FOR THE PURIFICATION OF FUNCTIONAL RISC-ASSOCIATED SMALL RNAS Final Rejection ETH Zürich
18469530 EXPANDING THE CHEMICAL SUBSTRATES FOR GENETIC CODE REPROGRAMMING Final Rejection The Board of Trustees of the University of Illinois
18043254 RNA STORAGE METHOD Non-Final OA KAO CORPORATION
18268722 Pet Food Compositions Non-Final OA Hill's Pet Nutrition, Inc.
18656010 ANIMAL MODELS, SCREENING METHODS, AND TREATMENT METHODS FOR INTRAOCULAR DISEASES OR DISORDERS Non-Final OA SMILEBIOTEK ZHUHAI LIMITED
18001429 CONJUGATE GROUP AND CONJUGATE Final Rejection MEDSHINE DISCOVERY INC.
18009566 POLYSACCHARIDE COMPOSITIONS AND THERAPEUTIC GELS Non-Final OA The University of Birmingham
18550498 LINE-1 INHIBITORS TO TREAT CNS AND SYSTEMIC DISEASES Non-Final OA TRANSPOSON THERAPEUTICS, INC.
18278844 PHARMACEUTICAL COMPOSITION FOR TREATMENT OF NEUROINFLAMMATION, COMPRISING ELEUTHEROSIDE B AS ACTIVE INGREDIENT Non-Final OA YEP BIO CO. LTD.
18236260 COMPOSITION COMPRISING FLAVIN ADENINE DINUCLEOTIDE (FAD), L-GSH, ATP AND MYRISTIC ACID, ALONE OR WITH A DRUG Non-Final OA BIO EVEN
18174111 FUNCTIONALIZED CELLULOSE NANOCRYSTALS STABILIZED SMART PICKERING EMULSION FOR ENHANCED PROBIOTIC DELIVERY Non-Final OA UNIVERSITY OF WATERLOO
18041642 USE OF A HEPARIN COMPOSITION IN THE TREATMENT OF VIRAL LUNG DISEASES, ACUTE AND/OR CHRONIC LUNG DISEASES BY SOFT MIST INHALER OR VIBRATION MESH TECHNOLOGY NEBULIZER THROUGH INHALATION ROUTE Non-Final OA ISTANBUL UNIVERSITESI REKTORLUGU
18007982 CANNABINOID-HYALURONIC ACID BIOCONJUGATES Non-Final OA LONDON PHARMACEUTICALS AND RESEARCH CORPORATION
17999910 COMPOUNDS FOR THE PREVENTION, TREATMENT AND DIAGNOSIS OF THROMBI Non-Final OA CARDIOVASCULAR LAB S.P.A
17916382 COMPOSITION AND METHOD FOR PRODUCING A COMPOSITION Final Rejection BIOPRONEO B.V.
17950520 2'-ALKYL OR 3'- ALKYL MODIFIED RIBOSE DERIVATIVES AND METHODS OF USE Non-Final OA Sanegene Bio USA Inc.
17637906 Edible Formulations Based on Active Ingredients and Arginine Non-Final OA GRAAL S.R.L.

Facing This Examiner?

IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.

Build Your Strategy

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month